Differential display of genes expressed in the filarial nematode Litomosoides sigmodontis reveals a putative phosphate permease up-regulated after depletion of Wolbachia endobacteria

International Journal of Medical Microbiology : IJMM
U HeiderKenneth Pfarr

Abstract

Mutualist symbiotic Wolbachia endobacteria are found in most filarial nematodes. Wolbachia are essential for embryogenesis and for larval development into adults, and thus represent a new target for anti-filarial drug development. Tetracycline antibiotics deplete Wolbachia in animal model filaria Litomosoides sigmodontis and Brugia pahangi, as well as in the human parasites Brugia malayi, Onchocerca volvulus and Wuchereria bancrofti. Very little is known about the molecular details of the symbiotic interaction between Wolbachia and filarial nematodes. Nematode genes that respond to anti-Wolbachia antibiotic treatment may play important roles in the symbiosis. Differential display PCR was used to detect several candidate genes that are up-regulated after 3, 6, 15, 30 and 36 days of tetracycline treatment. One of these genes, Ls-ppe-1, was similar to a family of phosphate permeases, and had putative orthologues in O. volvulus and B. malayi. Ls-ppe-1 steady-state mRNA levels were elevated by day 3-6 of treatment, and remained elevated through to 70 days post-treatment. In Caenorhabditis elegans, the knockdown of a homologous phosphate permease results in embryonic lethality, with the production of degenerating embryos, a phenotype...Continue Reading

References

Jan 1, 1975·Transactions of the Royal Society of Tropical Medicine and Hygiene·D J McLarenM G Simpson
Oct 1, 1996·International Journal for Parasitology·M Blaxter, L Liu
Dec 16, 1998·Science·UNKNOWN C. elegans Sequencing Consortium
Mar 2, 1999·Methods : a Companion to Methods in Enzymology·G M Poirier, M G Erlander
Oct 24, 2000·Tropical Medicine & International Health : TM & IH·E A Ottesen
Nov 18, 2000·Lancet·A AbioseH Remme
Feb 27, 2001·Nucleic Acids Research·L R BaughC P Hunter
Nov 28, 2001·European Journal of Biochemistry·F J ThompsonE Devaney
Apr 20, 2002·Current Opinion in Infectious Diseases·M J Taylor, A Hoerauf
Sep 27, 2002·Genesis : the Journal of Genetics and Development·Jean-Marc ReichhartDavid Gubb
Jun 28, 2003·Methods : a Companion to Methods in Enzymology·Ravi S Kamath, Julie Ahringer
Oct 29, 2003·Trends in Parasitology·David H MolyneuxMark J Taylor
Nov 19, 2003·PLoS Biology·Lincoln D SteinRobert H Waterston
Dec 19, 2003·Nucleic Acids Research·John ParkinsonMark Blaxter
Apr 22, 2004·Trends in Parasitology·Elodie GhedinBarton E Slatko
May 17, 2006·Trends in Ecology & Evolution·Katelyn Fenn, Mark Blaxter

❮ Previous
Next ❯

Citations

Jan 27, 2007·Current Infectious Disease Reports·Kelly L Johnston, Mark J Taylor
Feb 11, 2012·Journal of Biomedical Science·Ramakrishna U RaoGary J Weil
Nov 15, 2007·PloS One·Sanjay KumarClotilde K S Carlow
Aug 23, 2012·PloS One·Yan FuGuangyou Yang
Apr 22, 2008·Environmental Microbiology·Kathryn E Gibson, Yasuko Rikihisa
Dec 6, 2012·Cellular Microbiology·Mark J TaylorLouise Ford
Mar 31, 2017·PLoS Neglected Tropical Diseases·Alexandra GroteElodie Ghedin

❮ Previous
Next ❯

Related Concepts

Related Feeds

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.